Poster 2 Israel Gomez Sanchez


To evaluate the clinical findings and treatment outcomes in a patient with Branch retinal vein occlusion.


To report a case of BRVO in a 60 years old patient, hypertensive who was treated, two days from diagnosis, with PPV and liberation of adventitia, with success. Two weeks afterwards developed a macular oedema, which was treated with a Dexamethasone intravitreal implant (Ozurdex ®). The macular oedema disappeared in less than a week maintaining the BCVA. Three weeks after a retinal detachment appeared and was successfully treated. In the following days the BCVA felt coinciding with a cataract coming up. The Cataract was removed.


The treatment with mechanical adventitia liberation and intravitreal implant was effective.


  1. Should we avoid the treatment with PPV and adventitia liberation at the first sight and treat with intravitreal implant?
  2. Was intravitreal implant the cause of retinal detachment?
  3. Should we put infusion to inject in previously vitrectomized patient Ozurdex in eye?
  4. What is the role of ranibizumab (Lucentis ®) in our case?


Dexamethasone intravitreal is a proper treatment for macular oedema. We warn of the risk of retinal detachment in intravitreal Ozurdex- 22 gauge injector that in vitrectomized population, should be; avoided, made with infusion or reduce the thickness of the needle by the company.